Abstract
Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and non-cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer, 89% COVID-19+), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Chronic viral RNA carriers exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of non-conventional monocytes and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T helper cells, and non-naive Granzyme B+ FasL+, EomehighTCF-1high, PD-1+CD8+ Tc1 cells. Virus-induced lymphopenia worsened cancer-associated lymphocyte loss, and low lymphocyte counts correlated with chronic SARS-CoV-2 RNA shedding, COVID-19 severity and a higher risk of cancer-related death in the first and second surge of the pandemic. Lymphocyte loss correlated with significant changes in metabolites from the polyamine and biliary salt pathways as well as increased blood DNA from Enterobacteriaceae and Micrococcaceae gut family members in long term viral carriers. We surmise that cancer therapies may exacerbate the paradoxical association between lymphopenia and COVID-19-related immunopathology, and that the prevention of COVID-19-induced lymphocyte loss may reduce cancer-associated death.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04341207
Funding Statement
The Gustave Roussy sponsored clinical study on COVID-19 (ONCOVID; NCT NCT04341207 has been supported by the Fondation Gustave Roussy, the Dassault family, Malakoff Humanis, Agnes b., Izipizi, Ralph Lauren and Sanofi).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patients provided written informed consent. Protocol approval was obtained from an independent ethics committee (ethics protocol number EudraCT No: 2020-001250-21). Gustave Roussy Data Protection Officer (DPO) has evaluated this project and sent to the principal investigator a formalized-operational action plan about data protection compliance: patient's information, security measures, good practices about pseudonymization, etc. All of the DPO's recommendations has been applied by the research team.In agreement with MR004 in France, we reported the series to the national information science and liberties commission. Ethic committees: The Agence Nationale de securite du medicament et des produits de sante (FRANCE) gave the approval for the clinical trial No. EudraCT 2020-001250-21 (reference: MEDAECPP-2020-03-0012). The Committee of the Convention for the Protection of Individuals CPP Ile de France XI (FRANCE) approved the clinical trail (reference: 20025-75647). Decision made: CPP Ile de France XI and Agence Nationale de securite du medicament et des produits de sante authorized Gustave Roussy (No. CSET 2020/3078) for the clinical trial ONCOVID.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and materials availability: This study includes no data deposited in external repositories.
Abbreviations in alphabetic order
- ACE2
- Angiotensin-Converting Enzyme 2
- CD
- cluster of differentiation
- cMo
- classical monocytes
- COVID-19
- severe coronavirus infectious disease 2019
- Ct
- Cycle threshold
- CR
- Clinical Routine
- CXCR5
- C-X-C chemokine receptor type 5
- ECOG
- Eastern Cooperative Oncology Group performance status
- EM
- effector memory cells
- Eomes
- eomesodermin
- FC
- fold change
- FasL
- Fas ligand
- GzB
- granzyme B
- HCW
- health care worker
- ICOS
- Inducible T-cell co-stimulator
- ICU
- intensive care unit
- IFN
- Interferon
- Ig
- Immunoglobulin
- IL
- interleukin
- LVS
- long term viral RNA shedding
- NK
- Natural killer
- non-cMo
- non classical monocytes
- NSM
- Non-switch Memory
- Orf1b
- replicase open reading frame 1b
- PD
- progressive disease
- PD-1
- programmed cell death 1
- PMN
- polymorphonuclear cells
- RBD
- receptor-binding domain
- RdRP
- RNA-dependent RNA polymerase
- RNA
- ribonucleic acid
- rIL-7
- recombinant interleukin 7
- RT-qPCR
- quantitative reverse transcription-polymerase chain reaction
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- SD
- stable disease
- SVS
- short term viral RNA shedding
- Tc1
- cytotoxic T lymphocytes
- TCF-1
- Transcription factor 1
- TFH
- T follicular helper cells
- TR
- Translational Research.
